Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and ...

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...